

Orifarm PI A/S

Energivej 15
5260 Odense S
CVR No. 27347177

Annual report 2024

The Annual General Meeting adopted the
annual report on 05.06.2025

Matias Nørtoft Popp

Chairman of the General Meeting

Contents

Entity details	2
Statement by Management	3
Independent auditor's report	4
Management commentary	7
Income statement for 2024	9
Balance sheet at 31.12.2024	10
Statement of changes in equity for 2024	12
Notes	13
Accounting policies	16

Entity details

Entity

Orifarm PI A/S

Energivej 15

5260 Odense S

Business Registration No.: 27347177

Registered office: Odense

Financial year: 01.01.2024 - 31.12.2024

Board of Directors

Ole Michael Friis, Chairman

Hans Bøgh-Sørensen

Birgitte Bøgh-Sørensen

Mads Fink Eriksen

Executive Board

Thomas Brandhof

Auditors

Deloitte Statsautoriseret Revisionspartnerselskab

Weidekampsgade 6

2300 Copenhagen S

Statement by Management

The Board of Directors and the Executive Board have today considered and approved the annual report of Orifarm PI A/S for the financial year 01.01.2024 - 31.12.2024.

The annual report is presented in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2024 and of the results of its operations for the financial year 01.01.2024 - 31.12.2024.

We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.

We recommend the annual report for adoption at the Annual General Meeting.

Odense, 05.06.2025

Executive Board

Thomas Brandhof

Board of Directors

Ole Michael Friis
Chairman

Hans Bøgh-Sørensen

Birgitte Bøgh-Sørensen

Mads Fink Eriksen

Independent auditor's report

To the shareholder of Orifarm PI A/S

Opinion

We have audited the financial statements of Orifarm PI A/S for the financial year 01.01.2024 - 31.12.2024, which comprise the income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2024 and of the results of its operations for the financial year 01.01.2024 - 31.12.2024 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of this auditor's report. We are independent of the Entity in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Entity's ability to continue as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures in the notes, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.
- Plan and perform the audit of the financial statements to obtain sufficient appropriate audit evidence regarding the consolidated financial information of the entities or business units as a basis for forming an opinion on the financial statements. We are responsible for the direction, supervision and review of the audit work performed. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the management commentary

Management is responsible for the management commentary.

Our opinion on the financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.

Copenhagen, 05.06.2025

Deloitte

Statsautoriseret Revisionspartnerselskab
CVR No. 33963556

Jens Serup

State Authorised Public Accountant
Identification No (MNE) mne45825

Victor Fortmann Storm

State Authorised Public Accountant
Identification No (MNE) mne50626

Management commentary

Financial highlights

	2024	2023	2022	2021	2020
	DKK'000	DKK'000	DKK'000	DKK'000	DKK'000
Key figures					
Gross profit/loss	(58)	(65)	(73)	(76)	(57)
Operating profit/loss	(88)	(95)	(73)	(76)	(57)
Net financials	(10,949)	(10,656)	(3,606)	(2,486)	(805)
Profit/loss for the year	320,939	253,407	182,945	206,026	208,734
Total assets	1,330,336	1,070,912	817,787	857,664	659,123
Equity	1,161,019	940,668	687,448	759,954	563,785
Ratios					
Return on equity (%)	30.54	31.20	25.28	31.13	37.33
Equity ratio (%)	87.27	87.84	84.06	88.61	85.54

Financial highlights are defined and calculated in accordance with the current version of "Recommendations & Ratios" issued by the CFA Society Denmark.

Return on equity (%):

$\frac{\text{Profit/loss for the year} * 100}{\text{Average equity}}$

Equity ratio (%):

$\frac{\text{Equity} * 100}{\text{Total assets}}$

Primary activities

Orifarm PI A/S is part of Orifarm Group, which is a dynamic international player in the healthcare business.

The Company's primary activity is to own subsidiaries, that deal with import, repackaging and distribution of pharmaceuticals.

Development in activities and finances

The annual result shows a profit of kDKK 320,939 compared to a profit of kDKK 253,407 in 2023.

Profit/loss for the year in relation to expected developments

The Company's results for 2024 are considered satisfactory being higher than expectations as set out in the financial statements for 2023 mainly due to increased performance in subsidiaries.

Outlook

For 2025, Orifarm PI A/S expects a result before tax at 2024 level.

Statutory report on corporate social responsibility

Orifarm PI A/S is a part of Orifarm Group. Reference is made to the Group's statutory statement on CSR for 2024, which is presented in our ESG Report 2024 at www.orifarm.com/publications.

Statutory report on data ethics policy

Orifarm PI A/S is a part of Orifarm Group. Orifarm Group has decided to publish its statutory report on data ethics with our ESG report 2024. The ESG reports are available at www.orifarm.com/publications.

Events after the balance sheet date

From the reporting date until today, no events have occurred which could change the assessments made in the Annual Report.

Income statement for 2024

	Notes	2024 DKK'000	2023 DKK '000
Other external expenses		(58)	(65)
Gross profit/loss		(58)	(65)
Staff costs	1	(30)	(30)
Operating profit/loss		(88)	(95)
Income from investments in group enterprises		332,793	262,126
Other financial expenses	2	(10,949)	(10,656)
Profit/loss before tax		321,756	251,375
Tax on profit/loss for the year	3	(817)	2,032
Profit/loss for the year	4	320,939	253,407

Balance sheet at 31.12.2024

Assets

	Notes	2024 DKK'000	2023 DKK'000
Investments in group enterprises		1,325,648	1,068,846
Financial assets	5	1,325,648	1,068,846
Fixed assets		1,325,648	1,068,846
Trade receivables		0	2
Receivables from group enterprises		3,730	0
Tax receivable		958	2,064
Receivables		4,688	2,066
Current assets		4,688	2,066
Assets		1,330,336	1,070,912

Equity and liabilities

	Notes	2024 DKK'000	2023 DKK'000
Contributed capital	6	1,200	1,200
Reserve for net revaluation according to the equity method		1,086,389	829,587
Retained earnings		3,530	9,881
Proposed dividend		69,900	100,000
Equity		1,161,019	940,668
Payables to group enterprises		169,288	130,222
Other payables		29	22
Current liabilities other than provisions		169,317	130,244
Liabilities other than provisions		169,317	130,244
Equity and liabilities		1,330,336	1,070,912
Contingent liabilities	7		
Assets charged and collateral	8		
Related parties with controlling interest	9		
Group relations	10		

Statement of changes in equity for 2024

	Contributed capital DKK'000	Reserve for net revaluation according to the equity method DKK'000	Retained earnings DKK'000	Proposed dividend DKK'000	Total DKK'000
Equity beginning of year	1,200	829,587	9,881	100,000	940,668
Ordinary dividend paid	0	0	0	(100,000)	(100,000)
Exchange rate adjustments	0	(588)	0	0	(588)
Dividends from group enterprises	0	(75,403)	75,403	0	0
Profit/loss for the year	0	332,793	(81,754)	69,900	320,939
Equity end of year	1,200	1,086,389	3,530	69,900	1,161,019

Notes

1 Staff costs

	2024 DKK'000	2023 DKK'000
Average number of full-time employees	0	0

The Board of Directors does not receive remuneration. Pursuant to Section 98b(iii) of the Danish Financial Statements Act, remuneration to the members of the Executive Board is not disclosed.

2 Other financial expenses

	2024 DKK'000	2023 DKK'000
Financial expenses from group enterprises	10,918	10,632
Exchange rate adjustments	24	0
Other financial expenses	7	24
	10,949	10,656

3 Tax on profit/loss for the year

	2024 DKK'000	2023 DKK'000
Adjustment concerning previous years	1,775	32
Refund in joint taxation arrangement	(958)	(2,064)
	817	(2,032)

4 Proposed distribution of profit and loss

	2024 DKK'000	2023 DKK'000
Ordinary dividend for the financial year	69,900	100,000
Retained earnings	251,039	153,407
	320,939	253,407

5 Financial assets

	Investments in group enterprises DKK'000
Cost beginning of year	239,532
Cost end of year	239,532
Revaluations beginning of year	829,314
Exchange rate adjustments	(588)
Share of profit/loss for the year	332,793
Dividend	(75,403)
Revaluations end of year	1,086,116
Carrying amount end of year	1,325,648

Investments in subsidiaries	Registered in	Corporate form	Equity interest %
Orifarm A/S	Denmark	A/S	100.00
Orifarm Supply Holding A/S	Denmark	A/S	100.00
Orifarm Supply A/S	Denmark	A/S	100.00
Orifarm Supply s.r.o.	Czech Republic	s.r.o.	100.00
+ Orifarm s.r.o.	Czech Republic	s.r.o.	100.00
Aaragon Pharma s.r.o.	Czech Republic	s.r.o.	100.00
1 0 1 Carefarm s.r.o.	Czech Republic	s.r.o.	100.00
Orifarm d.o.o.	Croatia	d.o.o	100.00
Orifarm AB	Sweden	AB	100.00
Orifarm AS	Norway	AS	100.00
Orifarm Oy	Finland	Oy	100.00
Orifarm B.V.	Netherlands	B.V.	100.00
Orifarm UK Ltd.	United Kingdom	Ltd.	100.00
Orifarm Austria GmbH	Austria	GmbH	100.00
Orifarm Belgium BV	Belgium	BV	100.00
Aaragon Pharma GmbH	Germany	GmbH	100.00

6 Share capital

	Number	Par value DKK'000	Nominal value DKK'000
Shares	1,200,000	0,001	1,200
	1,200,000		1,200

The share capital is not divided into share classes.

7 Contingent liabilities

The Entity participates in a Danish joint taxation arrangement where HBS Capital ApS serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Entity is therefore liable for income taxes etc for the jointly taxed entities, and for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly taxed entities. The jointly taxed entities' total known net liability under the joint taxation arrangement is disclosed in the administration company's financial statements.

8 Assets charged and collateral

The Entity has provided guarantees under which the guarantors assume joint and several liability for Group enterprises' net debt with bank and credit institutions. The Group's total net debt in relation to this guarantee is booked at DKK 594.2m per 31 December 2024.

As securities for debt to banks, the Entity has pledged unlisted shares in certain subsidiaries with a total book value per 31 December 2024 of DKK 1,152m.

9 Related parties with controlling interest

All transactions with related parties which are not according with market conditions are conducted on arms length. There have been no such transactions in the financial year.

10 Group relations

Name and registered office of the Parent preparing consolidated financial statements for the largest group:
HBS Capital ApS, Odense, Central Business Registration Number 41 00 08 80.

Name and registered office of the Parent preparing consolidated financial statements for the smallest group:
Orifarm Group A/S, Odense, Central Business Registration Number 27 34 72 82.

Accounting policies

Reporting class

This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (large).

The accounting policies applied to these financial statements are consistent with those applied last year.

Minor reclassification are performed in comparative figures.

Consolidated financial statements

Referring to section 112(1) of the Danish Financial Statements Act, no consolidated financial statements have been prepared.

Recognition and measurement

Assets are recognised in the balance sheet when it is probable as a result of a prior event that future economic benefits will flow to the Entity, and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when the Entity has a legal or constructive obligation as a result of a prior event, and it is probable that future economic benefits will flow out of the Entity, and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is effected as described below for each financial statement item.

Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and measurement.

Income is recognised in the income statement when earned, whereas costs are recognised by the amounts attributable to this financial year.

Foreign currency translation

On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the balance sheet date are translated using the exchange rate at the balance sheet date. Exchange differences that arise between the rate at the transaction date and the rate in effect at the payment date, or the rate at the balance sheet date, are recognised in the income statement as financial income or financial expenses.

When recognising foreign subsidiaries and associates that are independent entities, the income statements are translated at average exchange rates for the months that do not significantly deviate from the rates at the transaction date. Balance sheet items are translated using the exchange rates at the balance sheet date. Goodwill is considered belonging to the independent foreign entity and is translated using the exchange rate at the balance sheet date. Exchange differences arising out of the translation of foreign subsidiaries' equity at the beginning of the year at the balance sheet date exchange rates and out of the translation of income statements from average rates to the exchange rates at the balance sheet date are classified directly as equity.

Exchange adjustments of outstanding accounts with independent foreign subsidiaries, which are considered part of the total investment in the subsidiary in question, are classified directly as equity.

Income statement

Other external expenses

Other external expenses include expenses relating to the Entity's ordinary activities, including expenses for stationery and office supplies, marketing costs, etc.

Referring to section 96 (3) in the Danish Financial Statement Act the Entity has decided not to show the fee to auditors. Reference is made to the information for the Group in the consolidated financial statements for Orifarm Group A/S.

Staff costs

Staff costs comprise salaries and wages, and social security contributions, pension contributions, etc for entity staff.

Income from investments in group enterprises

Income from investments in group enterprises comprises the pro rata share of the individual enterprises' profit/loss after full elimination of intra-group profits or losses.

Other financial expenses

Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, net capital or exchange losses on securities, payables and transactions in foreign currencies.

Tax on profit/loss for the year

Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.

The Entity is jointly taxed with all Danish subsidiaries. The current Danish income tax is allocated among the jointly taxed entities proportionally to their taxable income (full allocation with a refund concerning tax losses).

The jointly taxed companies are subject to the rules of section 11B of the Danish Companies Act governing interest deduction limitation. It has been agreed in the joint taxation that reduced interest deduction is recognised in the company in which the interest deduction has been reduced.

Balance sheet

Investments in group enterprises

Investments in group enterprises are recognised and measured according to the equity method. This means that investments are measured at the pro rata share of the enterprises' equity value plus unamortised goodwill and plus or minus unrealised intra-group profits or losses.

Group enterprises with negative equity value are measured at DKK 0. Any receivables from these enterprises are written down to net realisable value based on a specific assessment. If the Parent has a legal or constructive obligation to cover the liabilities of the relevant enterprise, and it is probable that such obligation will involve a loss, a provision is recognised that is measured at present value of the costs necessary to settle the obligations at the balance sheet date.

Upon distribution of profit or loss, net revaluation of investments in group enterprises is transferred to reserve for net revaluation according to the equity method in equity.

Investments in group enterprises are written down to the lower of recoverable amount and carrying amount.

The accounting policies applied to material financial statement items of group enterprises are the same methods as described above.

Receivables

Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.

Tax payable or receivable

Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax.

Dividend

Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity.

Other financial liabilities

Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.

Cash flow statement

Referring to section 86 (4) of the Danish Financial Statements Act, Orifarm PI A/S has not prepared any cash flow statement. Orifarm PI A/S is included in the consolidated cash flow statement in Orifarm Group A/S.